Product Details
Jamp Imatinib
Imatinib Mesylate400 mg
Tablet
DIN/PIN/NPN
02495074
Manufacturer
Jamp Pharma Corporation
Formulary Listing Date
2021-06-30
Unit Price
20.8314
Amount MOH Pays
20.8314
Coverage Status
General Benefit
ODB Formulary Therapeutic Classification
Therapeutic Note
Pharmacists and prescribers should be informed of a drug product's official indications as set out in Health Canada's approved product monograph.
ATC Code
L01EA01
Interchangeable Products
DIN/ PIN/ NPN | Brand name | Unit Price | Amount MOH pays |
---|---|---|---|
02399814 | Teva-Imatinib | 20.8314 | 20.8314 |
02431122 | PMS-Imatinib | 20.8314 | 20.8314 |
02397293 | Nat-Imatinib | 20.8314 | 20.8314 |
02492342 | Mint-Imatinib | 20.8314 | 20.8314 |
02495074 | Jamp Imatinib | 20.8314 | 20.8314 |
02504618 | Imatinib | 20.8314 | 20.8314 |
02253283 | Gleevec | 118.9900 | 20.8314 |
02355345 | Apo-Imatinib | 20.8314 | 20.8314 |
02490994 | Ach-Imatinib | 20.8314 | 20.8314 |
09857448 | Gleevec | 118.9900 | 20.8314 |
02521210 | Imatinib | 20.8314 | 20.8314 |
LU Clinical Criteria
NOEAP Criteria
Therapeutic Class | Reimbursement Criteria |
---|---|
Oncology Drugs | Imatinib
For the treatment of Metastatic Gastrointestinal Stromal Tumours (GIST) in patients with a tumour deemed to be NOT surgically resectable (metastatic or recurrent) Duration of Approval: 1 Year Renewal will be considered for patients with GIST who have benefited from or continue to benefit from therapy with Gleevec and are expected to continue to do so. Duration of Approval: 1 Year For the Adjuvant treatment of Gastrointestinal Stromal Tumours (GIST) in patients who meet the following criteria: Patients are at intermediate to high risk of recurrence following complete resection (using Miettinen relapse risk criteria, risk ≥ 20%) or has had tumor rupture before surgery or at surgery; AND
Note that the dosing regimen covered is no more than 400 mg daily. Duration of Approval: 3 Years Renewals will NOT be considered for patients receiving Gleevec for Adjuvant GIST. (i.e., Funding for adjuvant GIST is approved for up to 3 years. Longer coverage durations are not considered.) As of June 15, 2013, EAP approval letters will indicate PINs to be used for billing purposes. The PINs will allow the full price of each product to be submitted for reimbursement of EAP approved requests. Pharmacists should refer to the respective product monograph(s) for prescribing information and approved indications.
EAP Drug Request Form: |